Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Margaret Winkler

Internal Medicine Hammond, LA Medical Doctor

NPI 1457362147 CMS profile 575365

15744 Medical Arts Plaza, Hammond, LA 70403

Open in the dashboard

General payments

$4,024

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Margaret Winkler of Hammond, LA is reported in the CMS Open Payments database as having received $4,024 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $394 21
2024 General $491 26
2023 General $808 51
2022 General $727 47
2021 General $678 43
2020 General $276 16
2019 General $650 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Margaret Winkler
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Margaret Winkler were reported at $394. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Margaret Winkler Internal Medicine median Middle half National median
2019 $650 $159 $48–$570 $163
2020 $276 $119 $33–$402 $114
2021 $678 $135 $37–$521 $132
2022 $727 $141 $42–$496 $149
2023 $808 $149 $45–$519 $160
2024 $491 $154 $47–$537 $164
2025 $394 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $501 33 payments
  2. GlaxoSmithKline, LLC. $467 26 payments
  3. AstraZeneca Pharmaceuticals LP $401 23 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $328 20 payments
  5. Pfizer Inc. $309 20 payments
  6. Novartis Pharmaceuticals Corporation $233 13 payments
  7. Amgen Inc. $198 12 payments
  8. Novo Nordisk Inc $163 10 payments
  9. Scilex Pharmaceuticals Inc. $155 8 payments
  10. Esperion Therapeutics, Inc. $149 9 payments
  11. Other $1,120 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,965 247 payments
  2. Gift $59 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $453 25 payments
  2. VRAYLAR $313 20 payments
  3. BREZTRI $304 17 payments
  4. XIFAXAN $293 18 payments
  5. ENTRESTO $191 11 payments
  6. Repatha $151 9 payments
  7. NEXLETOL $149 9 payments
  8. AIMOVIG $103 6 payments
  9. PREVNAR - 13 $100 7 payments
  10. ZTLido $97 5 payments
  11. Other $2,949 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 155 drugs

Part D claims

9,755

Median for Internal Medicine: 777

Drug cost

$795,739

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 145 $153,149
Eliquis Apixaban Brand 146 $92,235
Ozempic Semaglutide Brand 84 $87,657
Humira Pen Adalimumab Brand 12 $81,740
Januvia Sitagliptin Phosphate Brand 67 $37,798
Linzess Linaclotide Brand 62 $36,265
Jardiance Empagliflozin Brand 49 $32,814
Tresiba Flextouch U-100 Insulin Degludec Brand 39 $23,004
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 33 $21,866
Farxiga Dapagliflozin Propanediol Brand 24 $17,019

The 10 drugs with the highest cost, of 155 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$93,615

Of which drugs: $224

Medicare patients

109

Average age 72

Services billed

1,540

70 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Diabetes 44%
Ischemic heart disease 32%
Heart failure 28%
COPD 28%
Chronic kidney disease 27%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 11 11 $219

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $76
$76 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $59
$59 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $49
$49 — —
REXULTI
  • Lundbeck LLC $37
$37 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $37
$37 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record